Related Experiment Video
Updated: Jun 15, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions
Dejan Ignjatovic1, Kristine Aasland, Marianne Pettersen
1Department of Gastrointestinal Surgery, Vestfold Hospital, Tonsberg, Norway. dejign@siv.no
Aim:
To determine the effect of a single dose of bevacizumab on adhesion formation in the rat cecum abrasion model.
Methods:
The cecum and parietal peritoneum of 38 male Wistar rats were abraded to promote adhesion formation. The rats were randomized into 2 groups: group 1 received bevacizumab (2.5 mg/kg) intraperitoneally, and group 2 received saline. On day 30 animals were killed, adhesions scored, and histopathological samples taken.
Results:
There was no wound dehiscence; there were 2 incision hernias (5.3%), 1 per group. Thirty-seven animals developed adhesions (97.4%). Adhesion grade and severity scores were significantly different between groups 1 and 2 at 2.7:1.6 (P = .018) and 3.8:2.7 (P = .007), respectively. There was no difference in adhesion square area (27.7:25.0%; P = .16), location (P = 1.00), or number (2.1:1.3; P = .06). Histopathology confirmed the statistical difference between groups (P = .049), and a highly significant correlation between results was shown (r = .758; P = .0001).
Conclusion:
A single dose of intraperitoneal bevacizumab significantly reduces grade and severity of abdominal adhesions in the cecum abrasion rat model.
